ChEBI: ZM 323881 is a member of the class of quinazolines carrying 2-fluoro-4-methyl-5-hydroxyanilino and benzyloxy substituents at positions 4 and 7 respectively. It has a role as a vascular endothelial growth factor receptor antagonist. It is a benzyl ether, an aromatic ether, a member of quinazolines, a secondary amino compound, a substituted aniline, a halophenol, a member of monofluorobenzenes, an organic cation and a fluorophenol. It is a conjugate base of a ZM 323881(1+).
zm323881 inhibits vegf-a-induced endothelial cell proliferation (ic50 = 8 nm) and vegf-r2 tyrosine phosphorylation (ic50 < 2 nm).vascular endothelial growth factor (vegf) increases vascular permeability and angiogenesis in many pathological conditions, such as cancer, arthritis, and diabetes. vegf activates vegf-receptor 1 (vegf-r1) and vegf-receptor 2 (vegf-r2) that autophosphorylate to initiate a signaling cascade resulting in angiogenesis and increased microvascular permeability. zm323881 is a potent and selective inhibitor of vegf-r2 tyrosine kinase.
zm323881 was found to inhibit vegf-a-induced endothelial cell proliferation (ic50 = 8 nm) and vegf-r2 tyrosine phosphorylation in vitro (ic50 < 2 nm) [1].
vegf-amediated increases in vascular permeability in perfused mesenteric microvessels in vivo were reversibly abolished by both zm323881 and the class iii receptor tyrosine kinase inhibitor ptk787/zk222584, suggesting that vegf-r2 phosphorylation is necessary for vegf-a-mediated increases in microvascular permeability in vivo [1].
[1] whittles ce, pocock tm, wedge sr, kendrew j, hennequin lf, harper sj, bates do. zm323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. microcirculation. 2002;9(6):513-22.
